Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant vs Zavegepant for Acute Migraine in the ED
NCT06985342Phase 4Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rimegepant, zavegepant in migraine, sponsored by Icahn School of Medicine at Mount Sinai. Started Jun 2025; status: terminated.
02
Drugs
rimegepantzavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06985342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06985342.